1. Home
  2. ONL vs TLSA Comparison

ONL vs TLSA Comparison

Compare ONL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.04

Market Cap

149.2M

Sector

Real Estate

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.34

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
TLSA
Founded
2021
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.2M
155.2M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
ONL
TLSA
Price
$2.04
$1.34
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
236.2K
129.0K
Earning Date
03-05-2026
05-06-2025
Dividend Yield
3.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$147,647,000.00
N/A
Revenue This Year
$4.10
N/A
Revenue Next Year
$3.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$0.73
52 Week High
$3.01
$2.60

Technical Indicators

Market Signals
Indicator
ONL
TLSA
Relative Strength Index (RSI) 34.59 46.06
Support Level $1.96 $1.27
Resistance Level $2.67 $1.59
Average True Range (ATR) 0.10 0.10
MACD -0.04 0.01
Stochastic Oscillator 16.97 40.00

Price Performance

Historical Comparison
ONL
TLSA

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: